Honeywell, headquartered in Morris Plains, New Jersey, is expanding its Spectra MG biofibre portfolio with a blue-hued fibre that provides a strong visual aid to better differentiate between multiple suture sets in more complex surgeries.

By creating clear colour contrast, the new fibre enables healthcare professionals to operate more accurately and efficiently, promoting greater safety for patients.

“We are providing major manufacturers the opportunity to modernise orthopaedic devices and improve surgical methods with our coloured Spectra MG biofibre,” said Abey Paul, business leader for Spectra MG at Honeywell. “This technology is extremely important for orthopaedic applications around the world, fostering successful procedures that protect both patients and professionals.”

Engineered to be both ultra-lightweight and ultra-high strength, Honeywell’s Spectra MG biofibre provides superior resistance to chemicals, fatigue and abrasion when compared to conventional polyethylene fibre, making it an optimal solution for minimally invasive surgeries. Earlier this year, the technology received ISO 13485 certification, the highest management standard for the medical device industry.

The addition of a coloured variety to the portfolio means the biomaterial can be utilised and trusted by a wide range of manufacturers building increasingly smaller, stronger and lighter devices. For the orthopaedic market, it provides new advantages for both existing devices and emerging trends used in corrective surgeries, such as robotics that reduce procedure durations and smart implants that flag dangerous bacterial presence. It will help support the growing worldwide market for orthopaedic devices, which is expected to reach a value of $43.1 billion by 2024.

In addition, by collaborating with and supplying directly to OEMs, Honeywell offers more tailored, flexible customer support to device manufacturers aiming to advance their equipment designs with coloured-fibre compatibility.

The new fibre is expected to be commercially available globally in the third quarter of 2022, following imminent approval from the New Medical Products Administration (NMPA). 

www.honeywell.com